NIH

Soligenix awarded NIAID contract

Wednesday, October 2, 2013 01:14 PM

Soligenix, a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures (MCMs) for which there remains an unmet medical need, has been awarded a contract valued at up to $6.4 million by the U.S. Department of Health and Human Service's NIH (specifically funded by the National Institute of Allergy and Infectious Diseases or NIAID).

More... »

PPD names VP for global product development

Monday, September 23, 2013 01:30 PM

CRO PPD has appointed Gregory Dennis, M.D., vice president of global product development. Dennis will be therapeutic area head, providing medical and scientific expertise for rheumatology, immunology and inflammatory diseases.

More... »

NIH awards $33m grant to Banner Alzheimer's Institute, study planned

Friday, September 20, 2013 11:14 AM

Banner Alzheimer's Institute (BAI) has announced a major prevention trial to evaluate a treatment in cognitively healthy older adults at the highest known genetic risk for developing Alzheimer's disease at older ages. An NIH grant, expected to total $33.2 million, will support this research.

More... »

NIH scientists pursue new therapies to improve rare disease drug development

Monday, September 16, 2013 08:00 AM

Four new preclinical drug development projects at the NIH will target a form of blindness and diseases characterized by cardiac problems. The projects were selected for their potential to treat specific rare diseases and to help scientists uncover new information that can be shared with other researchers.

More... »

Genia, Columbia, Harvard awarded DNA sequencing technology grant

Friday, September 13, 2013 01:10 PM

Genia Technologies has announced, as part of a research consortium with Columbia University and Harvard Medical School, it has received a Revolutionary Genome Sequencing Technologies—The $1,000 Genome grant from the National Human Genome Research Institute (NHGRI) of the NIH.  The grant, $5.25 million for three years, will be used in collaboration with investigators at Columbia and Harvard to further develop Genia's nanopore-based DNA sequencing platform that allows for single molecule, electrical, real-time analysis.  

More... »

Enanta receives additional $9.2m funding from NIAID

Wednesday, September 4, 2013 03:54 PM

The National Institute of Allergy and Infectious Diseases (NIAID), a division of the NIH, has agreed to provide additional funding of $9.2 million to its existing contract with Enanta Pharmaceuticals, an R&D-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, to fund preclinical and early clinical development for a new class of bridged bicyclic antibiotics known as Bicyclolides.

More... »

Pediatric auditory brainstem implant clinical trial awarded NIH grant

Friday, August 23, 2013 11:48 AM

House Research Institute (HRI) and Los Angeles Children’s Hospital have announced final approval of grant funding by the NIH National Institute on Deafness and Communications Disorders (NIDCD) for a five-year, FDA-approved clinical trial of the auditory brainstem implant (ABI) in children.

More... »

Navidea awarded NIH SBIR grant

Wednesday, August 21, 2013 04:19 PM

Navidea Biopharmaceuticals, a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, has been awarded a Small Business Innovation Research (SBIR) grant from the National Institute On Aging (NIA) of the NIH in connection with the company's phase III clinical program for its NAV4694 beta-amyloid imaging agent as an aid in the differential diagnosis of Alzheimer's disease.

More... »

NIH awards Seattle BioMed $16.6 million tuberculosis grant

Friday, August 16, 2013 12:04 PM

Seattle BioMed, a U.S. independent nonprofit focused solely on infectious disease research, has been awarded a grant from the National Institute of Allergy and Infectious Diseases, part of the NIH, which will take a comprehensive systems approach to tuberculosis (TB) infection, harnessing the power of technology and systems biology to examine the progression from latent infection to disease. The grant will total up to $16.6 million over a five-year period.

More... »

Anne Lindblad promoted to president and CEO of EMMES

Monday, August 12, 2013 04:18 PM

EMMES has promoted executive vice president Dr. Anne Lindblad to president and chief executive officer. Lindblad replaces Dr. Donald (Don) Stablein, who has been named past president. Stablein, who joined the company in 1980, has been president/CEO since 1992. In his new role as past president, he will continue to provide project support and will be an ambassador for EMMES.

More... »